ATE201215T1 - Malariapeptide - Google Patents

Malariapeptide

Info

Publication number
ATE201215T1
ATE201215T1 AT95913269T AT95913269T ATE201215T1 AT E201215 T1 ATE201215 T1 AT E201215T1 AT 95913269 T AT95913269 T AT 95913269T AT 95913269 T AT95913269 T AT 95913269T AT E201215 T1 ATE201215 T1 AT E201215T1
Authority
AT
Austria
Prior art keywords
antigen
hla
peptides
microorganism
chosen
Prior art date
Application number
AT95913269T
Other languages
English (en)
Inventor
Adrian Vivian Sinton Hill
Michael Aidoo
Catherine Elizabeth Ma Allsopp
Ajit Lalvani
Magdalena Plebanski
Hilton Carter Whittle
Original Assignee
Oxxon Pharmaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxxon Pharmaccines Ltd filed Critical Oxxon Pharmaccines Ltd
Application granted granted Critical
Publication of ATE201215T1 publication Critical patent/ATE201215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT95913269T 1994-03-31 1995-03-30 Malariapeptide ATE201215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9406492A GB9406492D0 (en) 1994-03-31 1994-03-31 Malaria peptides
PCT/GB1995/000737 WO1995026982A2 (en) 1994-03-31 1995-03-30 Malaria peptides

Publications (1)

Publication Number Publication Date
ATE201215T1 true ATE201215T1 (de) 2001-06-15

Family

ID=10752882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913269T ATE201215T1 (de) 1994-03-31 1995-03-30 Malariapeptide

Country Status (6)

Country Link
EP (1) EP0753009B1 (de)
JP (2) JPH09510877A (de)
AT (1) ATE201215T1 (de)
DE (1) DE69520943T2 (de)
GB (1) GB9406492D0 (de)
WO (1) WO1995026982A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
JP4593106B2 (ja) 2001-07-02 2010-12-08 バイオインセプト、エルエルシー 着床前因子の新しいアッセイ方法および着床前因子ペプチド
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) * 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
CA2783107C (en) * 2009-12-05 2018-08-07 Ann-Kristin Mueller Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins
JP6166858B2 (ja) 2011-03-02 2017-07-19 バイオインセプト、エルエルシー 細胞内損傷の治療のための組成物および方法
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP3341739A4 (de) 2015-08-28 2019-07-10 BioIncept LLC Mutierte peptide und verfahren zur behandlung von subjekten damit
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028425A (en) * 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens

Also Published As

Publication number Publication date
GB9406492D0 (en) 1994-05-25
EP0753009B1 (de) 2001-05-16
WO1995026982A2 (en) 1995-10-12
JP2006180865A (ja) 2006-07-13
EP0753009A1 (de) 1997-01-15
DE69520943T2 (de) 2001-11-08
DE69520943D1 (de) 2001-06-21
WO1995026982A3 (en) 1996-02-15
JPH09510877A (ja) 1997-11-04

Similar Documents

Publication Publication Date Title
DE69520943D1 (de) Malariapeptide
Sjölander et al. The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties
McRobert et al. Distinct trafficking and localization of STEVOR proteins in three stages of the Plasmodium falciparum life cycle
Mahanty et al. Progress in the development of recombinant and synthetic blood-stage malaria vaccines
Miyahira et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice
Mahajan et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria
Walther et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
Rosa et al. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate
Franke et al. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites
Salamanca et al. Plasmodium falciparum blood stage antimalarial vaccines: An analysis of ongoing clinical trials and new perspectives related to synthetic vaccines
DE69833755D1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
ATE411043T1 (de) Verfahren von dna-impfung
Calvo-Calle et al. A linear peptide containing minimal T-and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge
DE69333468D1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
Franke et al. A subdominant CD8+ cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture
PE97298A1 (es) Composicion para vacunas
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
BenMohamed et al. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides
Holder et al. Human immune response to MSP-1
Belperron et al. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum
Miyata et al. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization
Coban et al. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen
Da Fonseca et al. Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides
DE69836976D1 (de) Neospora impstoff
NZ213303A (en) Plasmodium protein, dna sequence and vaccine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee